USA flag logo/image

An Official Website of the United States Government

Reagents for Vector Production for Hematopoietic Gene TX

Award Information

Agency:
Department of Health and Human Services 		Branch:
N/A 		Award ID:
24873 		Program Year/Program:
1994 / SBIR
Agency Tracking Number:
24873 		Solicitation Year:
N/A 		Solicitation Topic Code:
N/A 		Solicitation Number:
N/A
Small Business Information
QUALITY BIOLOGICAL, INC.
QUALITY BIOLOGICAL, INC. 7581 LINDBERGH DRIVE GAITHERSBURG, MD 20879
View profile »
Woman-Owned: No
Minority-Owned: Yes
HUBZone-Owned: Yes
 
Phase 1
Fiscal Year: 1994
Title: Reagents for Vector Production for Hematopoietic Gene TX
Agency: HHS
Contract: 1 R43 CA63979-1,
Award Amount: $81,000.00
 

Abstract:

The goal of this research is to develop critical reagents that will support the production of highvector titers for transfusion medicine, ie. hematopoietic gene therapy for treatment of blood disordersas well as other applications. Attempts at concentrating these vectors has generally resulted in asignificant loss of infectious activity. One possibility is that the virus titer may be dependent upon thecomposition of the medium in which the viral producing cells (VPC) are grown; therefore, we will studydifferent media compositions in an effort to improve the vector titer produced by the VPC. A secondissue for the medium design is the safety and infusibility of the medium into human patients. The abilityto produce the vector supernatant in reagent medium would minimize the risk of immunizing the patientagainst foreign serum proteins in the media that might produce toxicities that could limit the usefulnessof the therapy. This would allow the direct injection of high titer virus and reduce the treatment timerequired for injected autologous VPC to produce the vectors. As a model system the PA3l7/LNL6packaging cell line that contains the LNL6 vector will be employed. The LNL6 vector carries the bacterialgene for neomycin resistance. Vector titer will be assessed using G418 resistant colony forming unitsby the G418 selection of infected NIH-3T3 fibroblasts. The regent medium will be developed with theeventual goal of producing a medium that is destined for direct infusibility into human patients.

Principal Investigator:

Ronald Brown
3018409331

Business Contact:

Small Business Information at Submission:

Quality Biological, Inc.
7581 Lindbergh Drive Gaithersburg, MD 20879

EIN/Tax ID:
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No